preparation including a pharmaceutically acceptable carrier.

## REMARKS

The present amendments are submitted as a consequence of telephone interviews conducted between Examiner James Wilson and the undersigned on or about May 1 and May 5, 1997, in which Examiner Wilson stated that applicant's amendment in response to the September 10, 1996 Official Action would not result in allowance of the application, in view of the references submitted with applicant's Supplemental Information Disclosure Statement filed March 7, 1997. It was the Examiner's position in this regard that certain subject matter within applicant's claims overlap with subject matter claimed in U.S. Patents Nos. 5,424,331, 5,498,631 and 5,569,459, thus preventing allowance of applicant's claims as then presented.

The claim amendments submitted herewith are believed to eliminate any overlap with the above-mentioned U.S. patents.

Entry of the foregoing amendments is respectfully requested, as these amendments are believed to put this application in condition for allowance.

In view of the present amendments, the issuance of a Notice of Allowance is in order and such action is earnestly solicited.

Respectfully submitted,

DANN, DORFMAN, HERRELL AND SKILLMAN A Professional Corporation

PTO Registration No. 27,643

Telephone: (215) 563-4100